Navigation Links
Schering-Plough Addresses Major Milestones and Challenges in,Treatment of Patients With Chronic Hepatitis C

r 800 mg TID in combination with PEGINTRON and REBETOL in patients chronically infected with HCV genotype 1 who were nonresponders to previous peginterferon and ribavirin combination therapy. The study involves approximately 350 patients at centers in the United States and Europe. All study participants have completed treatment and are in the follow-up phase. Sustained virological response data from this study will be available later in 2007, and will help guide future clinical development of boceprevir.

Key Data Presentations at EASL

Peginterferon Alfa-2b and Ribavirin for 14 or 24 Weeks in Patients with HCV Genotype 2 or 3 and Rapid Virological Response, The North-C Trial. Dalgard, O. et al. Oral presentation, Sunday, April 15, at 13:15, General Session 4.

A Pegylated Interferon Alfa-2b Dose Reduction in HCV 1B Patients with Rapid Viral Response Does Not Affect Sustained Virological Response. Napoli, N. et al. Poster presentation, Thursday, April 12.

Comparison of Early Virologic Response Among Patients with Chronic Hepatitis C Infected with Genotype Non 2/3 Treated with Pegylated Interferon Alfa-2b and Ribavirin in Dependence with Hepatic Fibrosis Stages. Berak, H. et al. Poster presentation, Thursday, April 12.

Combination of Two Hepatitis C Virus Inhibitors, SCH 503034 (Boceprevir) and NM107 (the active moiety of NM283, valopicitabine), Provides Enhanced Anti-Replicon Activity and Suppresses Emergence of Resistant Replicons. Ralston, R. et al. Late-breaker poster presentation, Thursday, April 12.

Favorable Cross-Resistance Profile of Two Novel Hepatitis C Virus Inhibitors, SCH 503034 (Boceprevir) and HCV-796, and Enhanced Anti-Replicon Activity Mediated by the Combined Use of Both Compounds. Howe, A.Y. et al. Poster presentation Thursday, April 12.

SCH 503034 (Boceprevir), an Oral HCV Protease Inhibitor, is Well Tolerated in Patients with Varying Degrees of Hepatic Impairment. Preston, R.A., et al. Poster present
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
2. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
3. New Position Statement from The North American Menopause Society Addresses Use of Local Estrogen for Treatment of Vaginal Atrophy in Postmenopausal Women
4. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
5. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
6. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
7. Pooled Studies Showed Desvenlafaxine Succinate Significantly Improved Painful Symptoms and Anxious Symptoms Associated with Major Depressive Disorder in Adults, Compared With Placebo
8. Six-Week Investigational Study In Adults With Major Depressive Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole Therapy With Antidepressants
9. Major Manufacturer of Unapproved and Adulterated Drugs
10. Exforge Helps Vast Majority of Patients Effectively Control Their Blood Pressure After Failing on Other Medicines, According to New Clinical Data
11. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
Post Your Comments:
(Date:8/20/2014)... , Aug. 20, 2014 The National ... the latest results achieved by the real-time, pseudoephedrine ... the National Precursor Log Exchange (NPLEx), automatically blocks ... track down meth offenders and make arrests. Data ... Kansas blocked the sale of ...
(Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com announces ... in its catalogue: The Impact of ... http://www.reportlinker.com/p01618927/The-Impact-of-Healthcare-Reform-PPACA-On-the-US-IVD-Industry.html ... 3590) is complex legislation that affects virtually every ... provisions are beginning to take effect now. IVD ...
(Date:8/20/2014)... 20, 2014 Research and Markets ... "Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and ... report to their offering. A ... and geography) - Size, Share, Global Trends, Company ... and Forecast, 2013 - 2020", suggests that the ...
Breaking Medicine Technology:Kansas's Stop-Sale System Achieves Significant Results In Battle Against Meth 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 3The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 4The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 5The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 6Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and Geography) - Research Report, 2013 - 2020 2
... 2012  Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today ... 2012.  For the first quarter of 2012, the Company reported ... compared with a net income of $2.9 million, or $0.05 ... $3.8 million change in operating results is primarily due to ...
... Janssen Research & Development, LLC, (Janssen), announced today ... to the U.S. Food and Drug Administration (FDA) seeking ... an oral anticoagulant, to treat patients with deep vein ... recurrent venous thromboembolism (VTE). These submissions are ...
Cached Medicine Technology:Neurocrine Biosciences Reports First Quarter 2012 Results 2Neurocrine Biosciences Reports First Quarter 2012 Results 3Neurocrine Biosciences Reports First Quarter 2012 Results 4Neurocrine Biosciences Reports First Quarter 2012 Results 5Neurocrine Biosciences Reports First Quarter 2012 Results 6Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 2Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 3Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 4Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 5Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 6Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 7Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 8
(Date:8/20/2014)... Denver, Colorado (PRWEB) August 21, 2014 ... filled with celebrities making pleas for donations to fight ... funds will be well-known national companies and brands through ... the public’s, the 2013 MDA Telethon raised nearly $60 ... as Zinga Frozen Yogurt franchisees, cause-related marketing ...
(Date:8/20/2014)... 21, 2014 Recently, UWDress.com, the distinguished ... selection of birthday party dresses for girls . ... are well-designed and exquisitely handmade by experienced specialists. Now, ... percent off. , The company’s new items come in ... short knee length frocks, long elegant backless gowns and ...
(Date:8/20/2014)... 2014 The International Board ... an organization recognizing professionals dedicated to promoting quality ... that with a certificate in autism , ... the Autism Spectrum have a way to show ... This, in turn, say IBCCES representatives, increases the ...
(Date:8/20/2014)... 19, 2014 (HealthDay News) -- A group representing U.S. ... a flu shot. According to the American College ... recent years have upheld the safety and effectiveness of ... highly infectious and can be particularly dangerous to pregnant ... other complications," Dr. Laura Riley, chair of the college,s ...
(Date:8/20/2014)... that the immune system is defective in people suffering from ... have ongoing issues with pain. , The research the ... help to explain why some painkillers may not offer satisfactory ... to 10% of the community. There are different forms ... which often has the greatest impact on sufferers, quality of ...
Breaking Medicine News(10 mins):Health News:On Eve of Big Telethon, Froyo Businesses Participate but Also Go Their Own -- Local Way 2Health News:On Eve of Big Telethon, Froyo Businesses Participate but Also Go Their Own -- Local Way 3Health News:Cheap Birthday Party Dresses for Girls Now Available at UWDress.com 2Health News:National Autism Certificate Credentialing Board IBCCES Increases Job Placement Opportunities for Those Dedicated to Working Within the Autism Spectrum 2Health News:National Autism Certificate Credentialing Board IBCCES Increases Job Placement Opportunities for Those Dedicated to Working Within the Autism Spectrum 3Health News:All Pregnant Women Need Flu Shot: Ob/Gyn Group 2Health News:Pain treatments less effective for those with irritable bowel 2
... on knees can also repair damaged ankles claim the ... repairing knee injuries, but it is also a valuable ... minimally invasive surgical technique it is being applied in ... problems, including ligament damage, bone chips and recurrent pain ...
... disease, is becoming an elite disease as so much of ... As a result of such ongoing research, hyperhomocysteinemia (increased levels ... the risk factors.// ,Dr. O Mayer Jr and colleagues ... result of their study that beer may provide enough folate--a ...
... pharmaceutical companies hope to strike a pot of gold ... price war that is likely to escalate in coming ... lured many companies to develop anti-AIDS drugs and market ... to pricing. ,The anti-AIDS drug market, currently dominated ...
... is injurious to health"- this warning , printed in every cigarette ... of smoking in many. But now the fact that even a ... by the researchers of North Carolina. ,It is a well ... the diseases such as heart attack , cancer etc.,. ...
... little as 10 minutes of moderate exercise daily can improve mood ... fact that exercise has its benefit towars the physical asset. But ... as to how much exercise will benefit. This is based on ... bicycle for longer periods and did not find any benefits as ...
... and ulcerative colitis, often grouped together under inflammatory ... industrialized nations with stringent standards of public hygiene. ... human immune system from interacting with worms, bacteria ... properly...Yes! Doctors at the University of Iowa are ...
Cached Medicine News:Health News:Arthroscopy for Ankles 2Health News:WORM! WORM! all the way 2
... This type of anchor is generally utilized when ... directly into the bone. Unlike other anchors that ... anchor does not have that limitation. The only ... is a mallet. The 4.4mm Stainless Steel Anchor ...
... Yasushi Nakao, M.D., Smith & Nephew ... flexor,tendon release for fingers and thumbs ... approach is designed to decrease patient ... of releasing the A1 pulley under ...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Medicine Products: